Key result
Labetalol infusion cuts SBP by ~59 mm Hg in acute MI with sustained hypertension.
Why the study?
The haemodynamic effects and safety of labetalol infusion for treating hypertension in acute myocardial infarction were not well characterized.
Answers are grounded in this paper and cite their sources.
BP and HR reductions with labetalol in hypertensive AMI leave open its role versus modern agents; hypothesis-generating only.
The haemodynamic effects of labetalol infusion (mean dose 1 mg/min) were measured in seven patients with sustained hypertension complicating acute myocardial infarction. Four of the patients had severe left ventricular failure. A fall in both systolic (mean 185 to 126 mm Hg) and diastolic (mean 87 to 68 mm Hg) blood pressure occurred in all patients. Cardiac index fell from 2.5 to 2.0 l/min/m2; systemic vascular resistance was not affected. Heart rate slowed from 83 to 70 beats/ min. Labetalol lowered pulmonary artery pressure in the patients with left ventricular failure. Labetalol is an effective antihypertensive agent in patients with acute myocardial infarction and our results suggest it is safe provided cardiac output is within or near the normal range. It seems not to be contraindicated in the presence of pulmonary oedema. The effects imply that myocardial oxygen requirements will be reduced. The implications for limitation of infarct size in patients presenting early after acute infarction should be determined.
No takes yet. Share an insight, caveat, or question.
Timmis et al. (1980) studied Sustained hypertension complicating acute myocardial infarction (n=7). Labetalol infusion was evaluated on Haemodynamic effects (blood pressure, cardiac index, heart rate). Labetalol infusion effectively lowered systolic blood pressure from a mean of 185 to 126 mm Hg and diastolic pressure from 87 to 68 mm Hg in patients with AMI and sustained hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: